Regulation of Matrix Metalloproteinase (Matrixin) Genes in Blood Vessels: A Multi-Step Recruitment Model for Pathological Remodelling (original) (raw)
Article navigation
Review Articles| September 26 2003
Bristol Heart Institute, University of Bristol, Bristol, UK
Search for other works by this author on:
Bristol Heart Institute, University of Bristol, Bristol, UK
Search for other works by this author on:
J Vasc Res (2003) 40 (4): 329–343.
Abstract
Matrix metalloproteinases (MMPs; matrixins) are a family of structurally related enzymes that collectively promote turnover of all components of the extracellular matrix. Matrix turnover is required for vascular repair, but, if excessive, leads to pathologies that include aneurysm formation and atherosclerotic plaque instability. We review the positive and negative regulation of metalloproteinase gene induction. We propose that multiple steps of gene induction recruit a wider spectrum of MMPs, which may ultimately lead to a transition from matrix turnover to matrix destruction. Studying the detailed mechanisms involved may suggest possibilities for intervening selectively against pathological MMP induction.
References
Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999;274:21491–21494.
Dollery CM, McEwan JR, Henney AM: Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863–868.
Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: The good, the bad, and the ugly. Circ Res 2002;90:251–262.
Bendeck MP, Irvin C, Reidy MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res 1996;78:38–43.
Zempo N, Koyama N, Kenagy RD, Lea HJ, Clowes AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler Thromb Vasc Biol 1996;16:28–33.
George SJ, Angelini GD, Newby AC, Baker AH: Adenovirus mediated gene transfer of the human TIMP-1 gene inhibits smooth muscle cell migration and neointima formation in human saphenous vein. Hum Gene Ther 1998;9:867–877.
Cho A, Reidy MA: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;91:845–851.
Galis ZS, Johnson C, Godin D, Magid R, Shipley JM, Senior RM, Ivan E: Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling. Circ Res 2002;91:852–859.
Thyberg J, Blomgren K, Roy J, Tran PK, Hedin U: Phenotypic modulation of smooth muscle cells after arterial injury is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 1997;45:837–846.
Leppert D, Waubant E, Galardy R, Bunnett N, Hauser S: T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379–4389.
Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/Gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998;99:411–422.
Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JPM, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JFM, Shapiro SD, Baes M, Borgers M, Collen D, Daemen M, Carmeliet P: Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135–1142.
Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, Drew A, Eeckhout Y, Shapiro S, Lupu F, Collen D: Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997;17:439–444.
Pyo R, Lee JK, Shipley JM, Curci JA, Mao R, Ziporin SJ, Ennis TL, Shapiro SD, Senior RM, Thompson RW: Targeted gene disruption of matrix metalloproteinase-9 (gelatinase B) suppresses development of experimental abdominal aortic aneurysms. J Clin Invest 2000;105:1641–1649.
Silence J, Lupu F, Collen D, Lijnen HR: Persistence of atherosclerotic plaque but reduced aneurysm formation in mice with stromelysin-1 (MMP-3) gene inactivation. Arterioscler Thromb Vasc Biol 2001;21:1440–1445.
Sukhova GK, Schonbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P: Evidence for increased collagenolysis by interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999;99:2503–2509.
Herren B, Raines EW, Ross R: Expression of a disintegrin-like protein in cultured human vascular cells and in vivo. FASEB J 1997;11:173–180.
Springman EB, Angleton EL, Birkedal-Hansen H, Van Wart HE: Multiple mode of activation of latent human fibroblast collagenase: Evidence for the role of a cys73 active-site zinc complex in latency and a ‘cysteine switch’ mechanism for activation. Proc Natl Acad Sci USA 1990;87:364–368.
Brooks PC, Silletti S, von Schalscha TL, Friedlander M, Cheresh DA: Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 1998;92:391–400.
Gomis-Ruth F-X, Maskos K, Betz M, Bergner A, Huber R, Suzuki K, Yoshida N, Nagase H, Brew K, Bourenkov GP, Bartunik H, Bode W: Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature 1997;389:77–81.
George SJ: Tissue inhibitors of metalloproteinases and metalloproteinases in atherosclerosis. Curr Opin Lipidol 1998;9:413–423.
Ohuchi E, Imai K, Fujii Y, Sato H, Seiki M, Okada Y: Membrane type 1 matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules. J Biol Chem 1997;272:2446–2451.
Kahari V, Saarialho-Kere U: Matrix metalloproteinases in skin. Exp Dermatol 1997;6:199–213.
Aimes R, Quigley J: Matrix metalloproteinase-2 is an interstitial collagenase: Inhibitor-free enzyme catalyzes the cleavage of collagen fibrils and soluble native type I collagen generating the specific 3/4 and 1/4 length fragments. J Biol Chem 1995;270:5872–5876.
Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M: A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61–65.
Lemaitre V, O’Byrne TK, Borczuk AC, Okada Y, Tall AR, D’Armiento J: ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 2001;107:1227–1234.
Fukumoto Y, Libby P, Rabkin E, Varo N, Harada K, Hill CC, Lawler PR, Schoen FJ, Krane SM, Aikawa M: Genetically determined resistance to collagenase action alters content of collagen and smooth muscle cells in atheroma. J Am Coll Cardiol 2002;39:445A.
Lijnen HR, Van Hoef B, Vanlinthout I, Verstreken M, Rio MC, Collen D: Accelerated neointima formation after vascular injury in mice with stromelysin-3 (MMP-11) gene inactivation. Arterioscler Thromb Vasc Biol 1999;19:2863–2870.
Itoh T, Ikeda T, Gomi H, Nakao S, Suzuki T, Itohara S: Unaltered secretion of beta-amyloid precursor protein in gelatinase A (matrix metalloproteinase 2)-deficient mice. J Biol Chem 1997;272:22389–22392.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D: Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737–744.
Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999;99:81–92.
Zou YP, Hu YH, Mayr M, Dietrich H, Wick G, Xu QB: Reduced neointima hyperplasia of vein bypass grafts in intercellular adhesion molecule-1-deficient mice. Circ Res 2000;86:434–440.
Birkedal-Hansen H, Moore WGI, Bodden MK, Windsor LJ, Birkedal-Hansen B, De Carlo A, Engler JA: Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 1993;4:197–250.
Murphy G, Cockett MI, Stephens PE, Smith BJ, Docherty AJP: Stromelysin is an activator of procollagenase. Biochem J 1987;248:265–268.
Strongin AY, Collier I, Bannikov BL, Grant GA, Goldberg GI: Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270:5331–5338.
Galis ZS, Muszynski M, Sukhova GK, Simon-Morissey E, Unemori E, Lark MW, Amento E, Libby P: Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of extracellular enzymes required for extracellular matrix degradation. Circ Res 1994;75:181–189.
Fabunmi RP, Baker AH, Murray EJ, Booth RFG, Newby AC: Divergent regulation by growth factors and cytokines of 95-kDa and 72-kDa gelatinases and tissue inhibitors of metalloproteinases-1, -2 and -3 in rabbit aortic smooth muscle cells. Biochem J 1996;315:335–342.
Hanemaaijer R, Koolwijk P, Le Clercq L, de Vrie WJA, van Hinsbergh VWM: Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells. Effects of tumour necrosis factor α, interleukin 1 and phorbol ester. Biochem J 1993;296:803–809.
Bond M, Chase AJ, Baker AH, Newby AC: Inhibition of transcription factor NF-κB reduces matrix-metalloproteinase-1, -3 and -9 production by rabbit and human vascular smooth muscle cells. Cardiovasc Res 2001;50:556–565.
Chase A, Bond M, Crook MF, Newby AC: Role of NF-κB activation in metalloproteinase-1, -3 and -9 secretion by human macrophages in vitro and rabbit foam cells produced in vivo. Arterioscler Thromb Vasc Biol 2002;22:765–771.
George SJ, Zaltsman AB, Newby AC: Surgical preparative injury and neointima formation increase MMP-9 expression and MMP-2 activation in human saphenous vein. Cardiovasc Res 1997;33:447–459.
Webb KE, Henney AM, Anglin S, Humphries SE, McEwan JR: Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler Thromb Vasc Biol 1997;17:1837–1844.
Zaltsman AB, Newby AC: Increased secretion of gelatinases A and B from the aortas of cholesterol fed rabbits: Relationship to lesion severity. Atherosclerosis 1997;130:61–70.
Southgate KM, Fisher M, Banning AP, Thurston VJ, Fabunmi RP, Baker AH, Groves PH, Davies M, Newby AC: Upregulation of basement-membrane-degrading metalloproteinase secretion following balloon angioplasty of pig carotid arteries. Circ Res 1996;79:1177–1187.
Southgate KM, Mehta D, Izzat MB, Newby AC, Angelini GD: Increased secretion of basement membrane degrading metalloproteinases in pig saphenous vein into carotid artery interposition grafts. Arterioscler Thromb Vasc Biol 1999;19:1640–1649.
Bendeck MP, Zempo N, Clowes AW, Gelardy RE, Reidy MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res 1994;75:539–545.
Zempo N, Kenagy RD, Au T, Bendeck M, Clowes MM, Reidy MA, Clowes AW: Matrix metalloproteinases of vascular wall cells are increased in balloon-injured rat carotid artery. J Vasc Surg 1994;20:209–217.
Rajavashisth TB, Xu X-P, Jovinge S, Meisel SR, Xu X-O, Chai N-N, Fishbein MC, Kaul S, Cercek B, Sharifi B, Shah PK: Membrane type 1 matrix metalloproteinase expression in human atherosclerotic plaques. Evidence for activation by proinflammatory mediators. Circulation 1999;99:3103–3109.
Galis ZS, Kranshöfer R, Fenton JW, Libby P: Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular cells. Arterioscler Thromb Vasc Biol 1997;17:483–489.
Rajagopalan S, Meng XP, Ramasamy S, Harrison DG, Galis ZS: Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. J Clin Invest 1996;98:2572–2579.
Dollery CM, McEwan JR, Wang MS, Sang QXA, Liu YLE, Shi YE: TIMP-4 is regulated by vascular injury in rats. Circ Res 1999;84:498–504.
Zaltsman AB, George SJ, Newby AC: Increased secretion of tissue inhibitors of metalloproteinases-1 and -2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloproteinase activity. Arterioscler Thromb Vasc Biol 1999;19:1700–1707.
Fabunmi RP, Sukhova GK, Sugiyama S, Libby P: Expression of TIMP-3 in human atheroma and regulation in lesion-associated cells: A potential protective mechanism in plaque stability. Circ Res 1998;83:270–278.
Amorino GP, Hoover RL: Interactions of monocytic cells with human endothelial cells stimulate monocytic metalloproteinase production. Am J Pathol 1998;152:199–207.
Wesley RB, Meng X, Godin D, Galsi ZS: Extracellular matrix modulates macrophage functions characteristic to atheroma: Collagen type I enhances acquisition of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler Thromb Vasc Biol 1998;18:432–440.
Wallner K, Li C, Shah PK, Fishbein MC, Forrester JS, Kaul S, Sharifi BG: Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999;99:1284–1289.
Galt SP, Lindemann S, Medd D, Allen LL, Kraiss LW, Harris ES, Prescott SM, McIntryre TM, Weyrich AS, Zimmerman GA: Differential regulation of matrix metalloproteinase-9 by monocytes adherent to collagen and platelets. Circ Res 2001;89:509–516.
Galis Z, Asanuma K, Godin D, Meng X: N-acetyl-cysteine decreases the matrix-degrading capacity of macrophage-derived foam cells. New target for antioxidant therapy? Circulation 1998;97:2445–2453.
Galis ZS, Sukhova GK, Kranzhöfer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively express matrix-degrading proteases. Proc Natl Acad Sci USA 1995;92:402–406.
Feinberg MW, Jain MK, Werner F, Sibinga NES, Wiesel P, Wang H, Topper JN, Perrella MA, Lee M-E: Transforming growth factor-beta 1 inhibits cytokine-mediated induction of human metalloelastase in macrophages. J Biol Chem 2000;275:25766–25773.
Sarén P, Welgus HG, Kovanen PT: TNF-6 and IL-1 selectively induce expression of 92-kDa gelatinase by human macrophages. J Immunol 1996;157:4159–4165.
Mach F, Schonbeck U, Sukhova GK, Bonnefoy JY, Libby P: Ligation of CD40 on macrophage induces matrix metalloproteinases and tissue factor expression. Atherosclerosis 1997;134:280–281.
Malik N, Greenfield BD, Wahl AF, Kiener PA: Activation of human monocytes through CD40 induces matrix metalloproteinases. J Immunol 1996;156:3952–3960.
Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P: Expression of stromelysin-3 in atherosclerotic lesions: Regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 1999;189:843–853.
Schonbeck U, Mach F, Sukhova GK, Bonnefoy JY, Libby P: CD40 ligation on smooth muscle cells induces expression of matrix metalloproteinases: Implication for plaque rupture. Atherosclerosis 1997;134:252.
Herman MP, Sukhova GK, Libby P, Gerdes N, Tang N, Horton DB, Kilbride M, Breitbart RE, Chun MY, Schonbeck U: Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma – a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 2001;104:1899–1904.
Wu L, Fan J, Matsumoto S, Watanabe T: Induction and regulation of matrix metalloproteinase-12 by cytokines and CD40 signaling in monocyte/macrophages. Biochem Biophys Res Commun 2000;269:808–815.
Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: Relevance to stability of atherosclerotic plaque. Circulation 1999;99:420–426.
Xu X-P, Meisel SR, Ong JM, Kaul S, Cercek B, Rajavashisth TB, Sharifi B, Shah PK: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 1999;99:993–998.
Huang Y, Mironova M, Lopes-Virella MF: Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 1999;19:2640–2647.
Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994;94:2493–2503.
Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Allpers CE, Clowes AW: Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996;148:777–783.
Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme. Proc Natl Acad Sci USA 1996;93:9748–9753.
Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 1995;92:1565–1569.
Southgate KM, Davies M, Booth RFG, Newby AC: Involvement of extracellular matrix degrading metalloproteinases in rabbit aortic smooth muscle cell proliferation. Biochem J 1992;288:93–99.
Pauly RR, Passaniti A, Bilato C, Monticone R, Cheng L, Papadaopoulos N, Gluzband YA, Smith L, Weinstein C, Lakatta EG, Crow MT: Migration of cultured vascular smooth muscle cells through a basement membrane barrier requires type IV collagenase activity and is inhibited by cellular differentiation. Circ Res 1994;75:41–45.
James TW, Wagner R, White LA, Zwolak RM, Brinkerhoff CE: Induction of collagenase gene expression by mechanical injury in a vascular smooth muscle cell derived cell line. J Cell Physiol 1993;157:426–437.
Johnson JL, van Eys GJJM, Angelini GD, George SJ: Injury induces dedifferentiation of smooth muscle cells and increased matrix-degrading metalloproteinase activity in human saphenous vein. Arterioscler Thromb Vasc Biol 2001;21:1146–1151.
Yanagi H, Sasaguri Y, Sugama K, Morimatsu M, Nagasi H: Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis 1991;91:207–216.
Kennedy SH, Qin H, Lin L, Tan EML: Basic fibroblast growth factor regulates type-1 collagen and collagenase gene expression in human smooth muscle cells. Am J Pathol 1995;146:764–771.
Pickering JG, Ford CM, Tang B, Chow LH: Coordinated effects of fibroblast growth factor-2 on expression of fibrillar collagens, matrix metalloproteinases, and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1997;17:475–482.
Lee E, Grodzinsky AJ, Libby P, Clinton SK, Lark MW, Lee RT: Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler Thromb Vasc Biol 1995;15:2284–2289.
Schonbeck U, Mach F, Sukhova GK, Murphy C, Bonnefoy JY, Fabunmi RP, Libby P: Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes – a role for CD40 signaling in plaque rupture? Circ Res 1997;81:448–454.
Park HY, Kwon HM, Lim HJ, Hong BK, Lee JY, Park BE, Jang Y, Cho SY, Kim HS: Potential role of leptin in angiogenesis: Leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro. Exp Mol Med 2001;33:95–102.
Schneider D, Sobel B: Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. Clin Cardiol 1997;20:433–440.
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee K-H, Harrison DG, Tsao PS: Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress. Circ Res 2001;88:1291–1298.
Haas TL, Davis SJ, Madri JA: Three-dimensional type I collagen lattices induce coordinate expression of matrix metalloproteinases MT1-MMP and MMP-2 in microvascular endothelial cells. J Biol Chem 1998;273:3604–3610.
Yamaguchi S, Yamaguchi M, Yatsuyanagi E, Yun SS, Nakajima N, Madri JA, Sumpio BE: Cyclic strain stimulates early growth response gene product 1-mediated expression of membrane type 1 matrix metalloproteinase in endothelium. Lab Invest 2002;82:949–956.
Hojo Y, Ikeda U, Takahashi M, Sakata Y, Takizawa T, Okada K, Saito T, Shimada K: Matrix metalloproteinase-1 expression by interaction between monocytes and vascular endothelial cells. J Mol Cell Cardiol 2000;32:1459–1468.
Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P: Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 1997;94:1931–1936.
Mach F, Schonbeck U, Fabunmi RP, Murphy C, Atkinson E, Bonnefoy JY, Graber P, Libby P: T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism – implications for tubule formation. Am J Pathol 1999;154:229–238.
Yakubenko V, Lobb R, Plow E, Ugarova T: Differential induction of gelatinase B (MMP-9) and gelatinase A (MMP-2) in T lymphocytes upon VLA-4 mediated adhesion to VCAM-1 and the CS-1 peptide of fibronectin. Exp Cell Res 2000;260:73–84.
Baram D, Vaday GG, Salamon P, Drucker I, Hershkoviz R, Mekori YA: Human mast cells release metalloproteinase-9 on contact with activated T cells: Juxtacrine regulation by TNF-alpha. J Immunol 2001;167:4008–4016.
Fang KC, Wolters PJ, Steinhoff M, Bidgol A, Blount JL, Caughey GH: Mast cell expression of gelatinases A and B is regulated by kit ligand and TGF-beta. J Immunol 1999;162:5528–5535.
Johnson JL, Jackson CL, Angelini GD, George SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 1998;18:1707–1715.
Benbow U, Brinkerhoff CE: The AP-1 site and MMP gene regulation: What is all the fuss about? Matrix Biol 1997;15:519–526.
Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J: Structural analysis and promoter characterization of the human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000;242:75–86.
Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y: Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/Tcf4 complex in human colorectal cancers. Oncogene 2002;21:5861–5867.
Westermarck J, Kahari VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999;13:781–792.
Hu E, Mueller E, Oliviero S, Papaioannou V, Johnson R, Spiegelman B: Targeted disruption of the c-fos gene demonstrates c-fos-dependent and -independent pathways for gene expression stimulated by growth factors or oncogenes. EMBO J 1994;13:3094–3103.
Brauchle M, Gluck D, Di Padova F, Han JH, Gram H: Independent role of p38 and ERK1/2 mitogen-activated kinases in the upregulation of matrix metalloproteinase-1. Exp Cell Res 2000;258:135–144.
McCawley LJ, Li SN, Wattenberg EV, Hudson LG: Sustained activation of the mitogen-activated protein kinase pathway – a mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration. J Biol Chem 1999;274:4347–4353.
Ravanti L, Heino J, Lopez-Otin C, Kahari VM: Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J Biol Chem 1999;274:2446–2455.
Simon C, Goepfert H, Boyd D: Inhibition of the p38 mitogen-activated protein kinase by SB 203580 blocks PMA-induced Mr 92,000 type IV collagenase secretion and in vitro invasion. Cancer Res 1998;58:1135–1139.
Gum R, Wang H, Lengyel E, Juarez J, Boyd D: Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase- and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene 1997;14:1481–1493.
Genersch E, Hayess K, Neuenfeld Y, Haller H: Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: Involvement of Ras-dependent and -independent pathways. J Cell Sci 2000;113:4319–4330.
Cho A, Graves J, Reidy MA: Mitogen-activated protein kinases mediate matrix metalloproteinase-9 expression in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2000;20:2725–2532.
Hussain S: Signal pathways implicated in the growth factor and cytokine mediated up regulation of gelatinase B, collagense 1 and stromelysin-1 in rabbit aortic smooth muscle cells; PhD thesis, Bristol, University of Bristol, 2000, p 249.
Gutman A, Wasylyk B: The collagenase gene promoter contains a TPA and oncogene-responsive unit encompassing the PEA3 and AP-1 binding sites. EMBO J 1990;9:2241–2246.
Buttice G, Kurkinen M: A polyomavirus enhancer A-binding protein-3 site and ets-2 protein have a major role in the 12-o-tetradecanoyl phorbol-13-acetate response of the human stromelysin gene. J Biol Chem 1993;268:7196–7204.
Kirstein M, SanzL, Quinones S, Moscat J, Diazmeco MT, Saus J: Cross-talk between different enhancer elements during mitogenic induction of the human stromelysin-1 gene. J Biol Chem 1996;271:18231–18236.
White L, Maute C, Brinckerhoff C: ETS sites in the promoters of the matrix metalloproteinases collagenase (MMP-1) and stromelysin (MMP-3) are auxiliary elements that regulate basal and phorbol-induced transcription. Connect Tissue Res 1997;36:321–335.
Westermark I, Seth A, Kahari V-M: Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. Oncogene 1997;14:2651–2660.
Gum R, Lengyel E, Juarez J, Chen JH, Sato H, Seiki M, Boyd D: Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen-activated protein kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP-1 sequences. J Biol Chem 1996;271:10672–10680.
Ihle JN: STATs: Signal transducers and activators of transcription. Cell 1996;84:331–334.
Korzus E, Nagase H, Rydell R, Travis J: The mitogen-activated protein kinase and JAK-STAT signalling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem 1997;272:1188–1196.
Catterall JB, Carrere S, Koshy PJT, Degnan BA, Shingleton WD, Brinckerhoff CE, Rutter J, Cawston TE, Rowan AD: Synergistic induction of matrix metalloproteinase 1 by interleukin-1 alpha and oncostatin M in human chondrocytes involves signal transducer and activator of transcription and activator protein 1 transcription factors via a novel mechanism. Arthritis Rheum 2001;44:2296–2310.
Sanz L, Berra E, Municio MM, Dominguez I, Lozano J, Johansen T, Moscat J, Diazmeco MT: Zeta-PKC plays a critical role during stromelysin promoter activation by platelet-derived growth-factor through a novel palindromic element. J Biol Chem 1994;269:10044–10049.
Sanz L, Moscat J, Diaz-Meco MT: Molecular characterisation of a novel transcription factor that controls stromelysin expression. Mol Cell Biol 1995;15:3164–3170.
Crawford HC, Fingleton BM, Rudolph-Owen LA, Heppner Goss KJ, Rubinfeld B, Polakis P, Matrisian LM: The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883–2891.
Crawford HC, Fingleton B, Gustavson MD, Kurpios N, Wagenaar RA, Hassell JA, Matrisian LM: The PEA3 subfamily of Ets transcription factors synergizes with beta-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001;21:1370–1383.
Sato H, Kita M, Seiki M: v-Src activates the expression of 92 kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements: A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 1993;268:23460–23468.
Bond M, Fabunmi RP, Baker AH, Newby AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: An absolute requirement for transcription factor NF-κB. FEBS Lett 1998;435:29–34.
Yokoo T, Kitamura M: Dual regulation of IL-1ß-mediated matrix metalloproteinase-9 expression in mesangial cells by NF-κB and AP-1. Am J Physiol 1996;270:F123–F130.
Bond M, Baker AH, Newby AC: Nuclear factor kappa-B activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabbit dermal fibroblasts. Biochem Biophys Res Commun 1999;264:561–567.
Barchowsky A, Brinckerhoff CE, Vincenti MP: Activation of MMP-1 transcription through the NF-kappa B and MAPK/AP-1 pathways in primary synovial fibroblasts. Arthritis Rheum 1999;42:765.
Mengshol JA, Vincenti MP, Brinckerhoff CE: IL-1 induces collagenase-3 (MMP-13) promoter activity in stably transfected chondrocytic cells: Requirement for Runx-2 and activation by p38 MAPK and JNK pathways. Nucleic Acids Res 2001;29:4361–4372.
Vincenti MP, Coon CI, Brinckerhoff CE: Nuclear factor kappa B p50 activates an element in the distal matrix metalloproteinase 1 promoter in interleukin-1 beta-stimulated synovial fibroblasts. Arthritis Rheum 1998;41:1987–1994.
Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu X-P, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 2001;104:3103–3108.
Edfeldt K, Swedenborg J, Hansson GK, Yan Z-Q: Expression of toll-like receptors in human atherosclerotic lesions. A possible pathway for plaque activation. Circulation 2002;105:1158–1161.
Hussain S, Assender JW, Bond M, Wong L-F, Murphy D, Newby AC: Activation of protein kinase Czeta is essential for cytokine-induced metalloproteinase-1, -3, and -9 secretion from rabbit smooth muscle cells and inhibits proliferation. J Biol Chem 2002;277:27345–27352.
de Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA: The transcription factor NF-κB and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000;20:e83–e88.
Malinin NL, Boldin MP, Kovalenko AV, Wallach D: MAP3K-related kinase involved in NF-κB induction by TNF, CD95 and IL-1. Nature 1997;385:540–548.
Haas TL, Stitelman D, Davis SJ, Apte SS, Madri JA: Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J Biol Chem 1999;274:22679–22685.
Zhang DL, Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 2003;22:974–982.
Upchurch GR, Ford JW, Weiss SJ, Knipp BS, Peterson DA, Thompson RW, Eagleton MJ, Broady AJ, Proctor MC, Stanley JC: Nitric oxide inhibition increases matrix metalloproteinase-9 expression by rat aortic smooth muscle cells in vitro. J Vasc Surg 2001;34:76–82.
Uria JA, Jimenez MG, Balbin M, Freije JMP, Lopez-Otin C: Differential effects of transforming growth factor-beta on the expression of collagenase-1 and collagenase-3 in human fibroblasts. J Biol Chem 1998;273:9769–9777.
Kerr LD, Miller DB, Matrisian LM: TGF-ß1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence. Cell 1990;61:267–278.
White LA, Mitchell TI, Brinckerhoff CE: Transforming growth factor beta inhibitory element in the rabbit matrix metalloproteinase-1 (collagenase-1) gene functions as a repressor of constitutive transcription. Biochim Biophys Acta 2000;1490:259–268.
Lewis M, Amento EP, Unemori EN: Transcriptional inhibition of stromelysin by interferon-gamma in normal human fibroblasts is mediated by the AP-1 domain. J Cell Biochem 1999;72:373–386.
Ma ZD, Qin HW, Benveniste EN: Transcriptional suppression of matrix metalloproteinase-9 gene expression by IFN-gamma and IFN-beta: Critical role of STAT-1 alpha. J Immunol 2001;167:5150–5159.
Varga J, Yufit T, Brown RR: Inhibition of collagenase and stromelysin gene expression by interferon-gamma in human dermal fibroblasts is mediated in part via induction of tryptophan degradation. J Clin Invest 1995;96:475–481.
Schonbeck U, Mach F, Sukhova GK, Bonnefoy J-Y, Fabunmi RP, Libby P: Regulation of metalloproteinase expression in human vascular smooth muscle cells by lymphocytes. A role for CD40 signalling in plaque rupture? Circ Res 1997;81:448–454.
Mach F, Schonbeck U, Bonnefoy JY, Pober JS, Libby P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40 – induction of, collagenase, stromelysin and tissue factor. Circulation 1997;96:396–399.
Schroen DJ, Brinckerhoff CE: Nuclear hormone receptors inhibit matrix metalloproteinase (MMP) gene expression through diverse mechanisms. Gene Expr 1996;6:197–207.
Schroen DJ, Brinckerhoff CE: Inhibition of rabbit collagenase (matrix metalloproteinase-1; MMP-1) transcription by retinoid receptors: Evidence for binding of RARs/RXRs to the -77 AP-1 site through interactions with c-Jun. J Cell Physiol 1996;169:320–332.
Schneikert J, Peterziel H, Defossez PA, Klocker H, deLaunoit Y, Cato ACB: Androgen receptor-Ets protein interaction is a novel mechanism for steroid hormone-mediated down-modulation of matrix metalloproteinase expression. J Biol Chem 1996;271:23907–23913.
Barnes PJ, Karin M: Nuclear factor-κB – a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066–1071.
Marx N, Schonbeck U, Lazar MA, Libby P, Plutzky J: Peroxisome proliferator-activated receptor gamma activators inhibit gene expression and migration in human vascular smooth muscle cells. Circ Res 1998;83:1097–1103.
Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain PPARgamma: Differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998;153:17–23.
Ricote M, Huang JT, Welch JS, Glass CK: The peroxisome proliferator-activated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol 1999;66:733–739.
Shu H, Wong BM, Zhou GC, Li Y, Berger J, Woods JW, Wright SD, Cai TQ: Activation of PPAR alpha or gamma reduces secretion of matrix metalloproteinase 9 but not interleukin 8 from human monocytic THP-1 cells. Biochem Biophys Res Commun 2000;267:345–349.
Coussens LM, Fingleton B, Matrisian LM: Matrix metalloproteinase inhibitors and cancer: Trials and tribulations. Science 2002;295:2387–2392.
George SJ: Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. Expert Opin Investig Drugs 2000;9:993–1007.
Palinski W, Napoli C: Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler Thromb Vasc Biol 2002;22:1745–1750.
© 2003 S. Karger AG, Basel
2003
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$39.00
1 Karger Article Bundle Token
$150
Rental
This article is also available for rental through DeepDyve. 